Everolimus in Combination with Octreotide Long-Acting Repeatable in a First-Line Setting for Patients with Neuroendocrine Tumors: A 5-Year Update.

Abstract

BACKGROUND:

We previously presented data of this multicentric, phase II study showing that everolimus plus octreotide long-acting repeatable (LAR) for advanced neuroendocrine neoplasms (NENs), in the first line setting, is an active and safe treatment. We now present updated data at 5 years.

METHODS:

Patients with advanced well-differentiated, previously untreated neuroendocrine tumors of the gastroenteropancreatic tract and of the lung received octreotide LAR 30 mg plus everolimus 10 mg/day. The primary endpoint was the objective response rate (ORR). We performed an analysis of "long responder" patients and of time to progression (TTP) and overall survival (OS) at 5 years.

RESULTS:

Fifty patients were enrolled; the primary tumor site was: pancreas (14 patients), lung (11 patients), ileum (9 patients), jejunum/duodenum (2 patients), and unknown (14 patients). Seventeen (34%) of these patients have received treatment for more than 2 years. The median exposure to study drugs was 519.5 days (range 48-2,024). Currently 3 patients are still in treatment. The ORR (partial response + complete response) was 18% (95% confidence interval [CI] 7.4-28.6): complete response 1 patient (2%), partial response 8 patients (16%), stable disease 37 patients (74%). The median TTP was 33.6 months (95% CI 18.7-41.2) and the median OS was 61.0 months (95% CI 49.8-not reached).

CONCLUSION:

In this update of clinical outcome at 5-year follow-up, everolimus plus octreotide has been shown to be active in advanced NENs. The current analysis showed a further prolongation of TTP and a long exposure to the study drug without major side effects in the long term.

• Authors: Emilio Bajetta, Laura Catena, Sara Pusceddu, Francesca Spada, Claudio Iannacone, Italo Sarno, Giandomenico Di Menna, Lorenzo Dottorini, Anna Maria Marte
• Journal: Neuroendocrinology (Neuroendocrinology) Vol. 106 Issue 4 Pg. 307-311 ( 2018) ISSN: 1423-0194 [Electronic] Switzerland
• PMID: 28743120 (Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
• Copyright: © 2017 S. Karger AG, Basel.

Chemical References

• Delayed-Action Preparations
• Everolimus
• Octreotide

Topics

• Adult
• Aged
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Delayed-Action Preparations
• Disease-Free Survival
• Everolimus (administration & dosage, adverse effects)
• Female
• Humans
• Kaplan-Meier Estimate
• Male
• Middle Aged
• Neuroendocrine Tumors (drug therapy, mortality)
• Octreotide (administration & dosage, adverse effects)
• Treatment Outcome